Zaltrap, developed by Sanofi and Regeneron Pharmaceuticals, will compete with Roche Holding AG’s Avastin (bevacizumab) and Bristol-Myers Squibb Co's Erbitux (cetuximab).

Sanofi reported total sales of €34,947 million, an increase of 0.5%. The company suffered many patent expirations and were impacted by generic competition – net sales lost came to €1,345 ...

The anticipated boxing match between the legendary Mike Tyson and YouTuber-turned-boxer Jake Paul has been rescheduled for Friday, Nov. 15 at AT&T Stadium (Netflix, 8 p.m. ET). The bout was first ...

Sanofi has firmed up its position in the red-hot area of radiopharmaceuticals for cancer with the purchase of a €300 million ($325 million) stake in Orano Med, a subsidiary of French nuclear ...

Mike Tyson, of Brooklyn, New York, is a former heavyweight lineal champion known as "The Baddest Man on the Planet." Tyson, the youngest man to ever win a heavyweight title, retired in 2005, but ...

Sanofi has hit back on a decision by NICE not to recommend NHS use of Sarclisa as part of a regimen for relapsed and refractory multiple myeloma (RRMM), claiming the agency would not consider the ...

Sanofi has said it plans to start discussions about filing its oral BTK inhibitor tolebrutinib for multiple sclerosis, even though the drug only achieved its primary objective in one of three ...

Meanwhile, in December 2022, Sanofi walked away from a four-year-old partnership with Revolution Medicines focused on an SHP2 inhibitor, intended as a combination with KRAS inhibitors, including ...

Mike Murillo was bit by the radio bug at age 14, when he began his first part-time radio job. In 2004, while still in college at the University of Central Florida, Mike started working as a news ...

Without question, as New Zealand’s number one talk host, Mike Hosking sets the day’s agenda. The sharpest voice and mind in the business, Mike drives strong opinion, delivers the best talent ...

Sanofi is paying $175 million upfront to claim a share of an experimental vaccine developed by Johnson & Johnson’s pharma unit Janssen that aims to tackle a major cause of blood infections.